Barclays Positive on Jazz Pharmaceuticals (JAZZ) On Markman Ruling
Tweet Send to a FriendGet Alerts JAZZ Hot Sheet
Price: $61.53 +2.55%
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 8
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 8
Trade JAZZ Now!
Barclays commented on Jazz Pharmaceuticals (NASDAQ: JAZZ) following the Markman ruling in Jazz's patent litigation with generic challenger Roxane.
"The ruling clearly brought relief, with the Judge's ruling slightly in Jazz's favor regarding the formulation patents (the so-called '431 patent family) and overwhelmingly so regarding the patents over Jazz's proprietary distribution system (the so-called -730 family)," the firm notes. "The favorable outcome for the formulation patents is particularly important because many investors felt that Jazz's position was most vulnerable there. In particular, the Court's rejection of Roxane's proposal to limit pH-adjusting agents to just an "acid or base" is important because makes it more difficult for Roxane to succeed on non-infringement."
Barclays maintained tier Overweight rating and price target of $60.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $55.29 yesterday, with a 52 week range of $34.02-$56.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"The ruling clearly brought relief, with the Judge's ruling slightly in Jazz's favor regarding the formulation patents (the so-called '431 patent family) and overwhelmingly so regarding the patents over Jazz's proprietary distribution system (the so-called -730 family)," the firm notes. "The favorable outcome for the formulation patents is particularly important because many investors felt that Jazz's position was most vulnerable there. In particular, the Court's rejection of Roxane's proposal to limit pH-adjusting agents to just an "acid or base" is important because makes it more difficult for Roxane to succeed on non-infringement."
Barclays maintained tier Overweight rating and price target of $60.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $55.29 yesterday, with a 52 week range of $34.02-$56.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jazz Pharma (JAZZ) Could Be Takeout Target
- Leerink Swann Bullish on Insmed (INSM); Raises PT to $22
- UBS Raises PT on MEMC (WFR); Thinks Semi Sales Troughed in Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
